BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37562802)

  • 21. Radiotherapy target volume definition in newly diagnosed high grade glioma using
    Dissaux G; Dissaux B; Kabbaj OE; Gujral DM; Pradier O; Salaün PY; Seizeur R; Bourhis D; Ben Salem D; Querellou S; Schick U
    Radiother Oncol; 2020 Sep; 150():164-171. PubMed ID: 32580001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
    Wollring MM; Werner JM; Bauer EK; Tscherpel C; Ceccon GS; Lohmann P; Stoffels G; Kabbasch C; Goldbrunner R; Fink GR; Langen KJ; Galldiks N
    Neuro Oncol; 2023 May; 25(5):984-994. PubMed ID: 36215231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of Dynamic O-(2-[
    Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
    World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.
    Hutterer M; Nowosielski M; Putzer D; Jansen NL; Seiz M; Schocke M; McCoy M; Göbel G; la Fougère C; Virgolini IJ; Trinka E; Jacobs AH; Stockhammer G
    Neuro Oncol; 2013 Mar; 15(3):341-51. PubMed ID: 23335162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
    Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
    J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas.
    Rahm V; Boxheimer L; Bruehlmeier M; Berberat J; Nitzsche EU; Remonda L; Roelcke U
    J Nucl Med; 2014 Apr; 55(4):546-50. PubMed ID: 24566001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
    Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.
    Pyka T; Gempt J; Hiob D; Ringel F; Schlegel J; Bette S; Wester HJ; Meyer B; Förster S
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):133-141. PubMed ID: 26219871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
    Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
    Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience.
    Henriksen OM; Larsen VA; Muhic A; Hansen AE; Larsson HBW; Poulsen HS; Law I
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):103-112. PubMed ID: 26363903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
    Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
    J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma.
    Pöpperl G; Götz C; Rachinger W; Schnell O; Gildehaus FJ; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):792-800. PubMed ID: 16550381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging.
    Stadlbauer A; Prante O; Nimsky C; Salomonowitz E; Buchfelder M; Kuwert T; Linke R; Ganslandt O
    J Nucl Med; 2008 May; 49(5):721-9. PubMed ID: 18413402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.
    Jansen NL; Suchorska B; Wenter V; Eigenbrod S; Schmid-Tannwald C; Zwergal A; Niyazi M; Drexler M; Bartenstein P; Schnell O; Tonn JC; Thon N; Kreth FW; la Fougère C
    J Nucl Med; 2014 Feb; 55(2):198-203. PubMed ID: 24379223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
    Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
    Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
    Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FET PET differentiation of ring-enhancing brain lesions.
    Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
    J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[
    Langen KJ; Stoffels G; Filss C; Heinzel A; Stegmayr C; Lohmann P; Willuweit A; Neumaier B; Mottaghy FM; Galldiks N
    Methods; 2017 Nov; 130():124-134. PubMed ID: 28552264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
    Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
    J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
    Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
    Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.